Home
Journal Information
About
Aims and Scope
Contacts and Editorial Office
Editorial Board
Editor in Chief
Publisher
Conflicts of Interest
Editorial Policies
Publication Ethics
Nickan Research Institute policy
DISCLAIMER
Open Access
Journal Issues
Current Issue
In Press
Archive
Guidelines
For Authors
For Authors-New
For Reviewers
Peer Review Process in JRIP
Peer Review Process flowchart in JRIP
Authors agreement form
Checklist for review
Editorial Workflow
Publication Ethics and Malpractice Statement
Human and animal right
Informed Consent
Create Account
Login
Title
Author
Abstract
Keywords
First Name
Last Name
Search
eISSN
:
2345-2781
Submit Your Paper
Editorial Board
Aims and Scope
Publisher
Publication Fee
Contact Us
Archive
Indexing Information
Member of
Follower of
J Renal Inj Prev
. 2021;10(4): e35. doi:
10.34172/jrip.2021.35
Review
Sodium-glucose co-transporter 2 inhibitors (SGLT2i); as a preventive factor of kidney failure in patients with type 2 diabetes; a meta-analysis of randomized controlled trials
Dorsa Jahangiri
1
,
2
, Udit Narayan Padhi
3
, Henu Kumar Verma
4
, Bhaskar VKS Lakkakula
3
, Rohollah Valizadeh
5
,
6
, Hamid Nasri
1
*
Cited by CrossRef: 2
1- Cheng Q, Zou S, Feng C, Xu C, Zhao Y, Shi X, Sun M. Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. 2023;102(10):e33198
[Crossref]
2- Feng B, Yang F, Liu J, Sun Q, Meng R, Zhu D. Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice.
Journal of Diabetes and its Complications
. 2023;37(3):108409
[Crossref]